Endocrine Abstracts

Identifying effective strategies and underneath molecular signatures is crucial to combat certain metabolic diseases with increasing incidence such as obesity and MASLD (metabolic dysfunction-associated steatotic liver disease). The hepatic secretome plays a crucial role at controlling global energy metabolism and inflammation in MASLD. However, the interplay between diet composition and the eating architecture on the dynamic response of secretome as a tool to improve disease ...

Background: Cardiovascular disease accounts for about one-third of all premature deaths (ie, age <70) in Cuba. Yet, the relevance of major risk factors, including diabetes, systolic blood pressure (SBP), and body-mass index (BMI), to cardiovascular mortality in this population remains unclear.Methods: In 1996–2002, 146,556 adults were recruited from the general population in five areas of Cuba. Participants were interviewed, measured (height, we...

Introduction: Hypoglucemia is one of the most common endocrine symptoms and supposes a challenging in endocrine clinical practise. In most cases, are produced in relation with diabetes (drugs and diet). In other cases, there was an endogenous insulin production which cause the symptoms.Clinical report: A 58-year-old was attended in the Emergency Department with episodes of lightheadedness, diaphoresis, palpitation, tremulousness for month duration. In th...

Objective: After Cushing Syndrome (CS) is cured, up to 70% of patients develop chronic adrenal insufficiency (AI) and hypothalamus-pituitary-adrenal (HPA) axis dysfunction. A long-term treatment with glucocorticoids (GC) is mandatory to overcome AI. However, this treatment implies non-desired complications. Fibroblast growth factor (FGF21), a key regulator of metabolism, has a bidirectional relationship with GC that bypasses the negative feedback of the HPA axis. In this study...

Anamnesis: We report the case of a 54-year-old man who consulted for weight loss. He had been diagnosed with diabetes more than 20 years ago with good glycemic control (currently HbA1c 6.9%), no obesity, hypertension, or dyslipidaemia. A history of chronic pancreatitis and retinitis pigmentosa with eyelid ptosis. He maintains regular treatment with metformin, sitagliptin, repaglinide, ASA, Kreon and Pregabalin.Complementary testIn reference to the chief complaint, there had no...

Cushing’s syndrome (CS) is a hormonal disorder characterized by chronic high levels of circulating cortisol. Patients treated for CS develop chronic adrenal insufficiency (AI) and hypothalamus-pituitary-adrenal (HPA) axis dysfunction. Long-term treatment with glucocorticoids (GC) is mandatory to overcome AI. Fibroblast growth factor (FGF) -21, a key regulator of metabolism, has a bidirectional relationship with GC that bypasses the negative feedback of the HPA axis. In th...

Background: Pituitary tumours are commonly benign adenomas, accounting for 10-15% of all intracranial neoplasms. Among functioning pituitary tumours, prolactinomas are the most frequently observed in the clinic (about 40%). Dopamine, acting through the dopamine type 2 receptor (Drd2), is the main inhibitor of lactotroph proliferation and prolactin secretion, therefore, these tumours are usually treated with dopaminergic agonists with a high efficiency. However, there is a subs...

Introduction: The malignancy of the thyroglossal duct cyst is infrequent, 0.7 to 1% of the thyroglossal duct cysts, predominantly in women and euthyroid subjects, some associated with Hashimoto’s Thyroiditis. Clinical case: Male, 42 years old, with a 5-year history of a large anterior cervical tumor, diagnosed with Graves’ disease and thyroid orbitopathy. Cervical ultrasound reports right submandibular region mixed tumor mass 36 x30. mm with no...

Serum prolactin levels increase progressively from birth to adulthood in female and male rats, being higher in females from birth. Although this gradual increase was associated with concomitant maturation of prolactin-releasing and -inhibiting factors, these processes do not fully explain some sex differences observed. In in vitro studies, using lactotrophs in culture, from rats of different ages, in the absence of hypothalamic control, it was shown that the secretion...

A 46 year old female presented with 12 months history of secondary amenorrhoea. Prolactin was 4746 mIU/l without macroprolactin complexes, LH & FSH were low, oestradiol was undetectable. She had normal visual fields. No other clinical or biochemical features of pituitary dysfunction. She had no regular medication. Pituitary MRI was normal. She was started on cabergoline 250 mcg twice weekly which was subsequently increased to 500 mcg twice weekly. Repeat serum prolactin 5 ...